Skip to main content
Premium Trial:

Request an Annual Quote

Medicare Coverage Set for Genomic Health's Oncotype Dx Colon Cancer Test

NEW YORK (GenomeWeb News) – Genomic Health today announced it has attained Medicare coverage for its Oncotype Dx colon cancer test.

Palmetto GBA, the designated national contractor for the test, has created a formal coverage policy for all Medicare recipients with stage II colon cancer. The policy is effective for all claims for services performed on or after Sept. 18, the Redwood City, Calif.-based genomics testing service firm said.

Palmetto made its decision based on two large QUASAR and Cancer and Leukemia Group B clinical validation studies and additional clinical utility information.

As of June 30, more than 10,000 doctors in more than 60 countries had ordered more than 200,000 Oncotype Dx colon cancer and breast cancer tests, Genomic Health said.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.